Get the Stockscreener App
40.63
2.14%
0.85
Pre-market:
40.03
-0.60
-1.48%
Qiagen Nv stock is traded at $40.63, with a volume of 2.16M.
It is up +2.14% in the last 24 hours and down -16.43% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$39.78
Open:
$40.51
24h Volume:
2.16M
Relative Volume:
0.93
Market Cap:
$8.37B
Revenue:
$2.09B
Net Income/Loss:
$424.88M
P/E Ratio:
19.88
EPS:
2.0439
Net Cash Flow:
$447.20M
1W Performance:
+0.44%
1M Performance:
-16.43%
6M Performance:
-7.51%
1Y Performance:
+2.42%
1-Day Range:
$39.82
$41.03
1-Week Range:
$39.24
$41.03
52-Week Range:
$38.13
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
40.63 | 8.37B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.31B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 132.34B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.84B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 31.93B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.66B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution - AD HOC NEWS
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt ex - AD HOC NEWS
Portfolio Update: How does Qiagen NV score in quality rankings2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
Aug Gainers: Can Qiagen NV ride the EV waveTrade Volume Report & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Should You Add QIAGEN Stock to Your Portfolio for Now? - MSN
Why is Qiagen (QGEN) down 9.4% since last earnings report? - MSN
AI in Omics Studies Market is Going to Boom | Major Giants QIAGEN, Microsoft, NVIDIA - openPR.com
JPMorgan Chase & Co. Has $33.09 Million Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience - AD HOC NEWS
Breakout Zone: Is Qiagen NV part of any major index2026 Volume & Daily Growth Stock Investment Tips - baoquankhu1.vn
Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors - MSN
Institution Moves: Is Qiagen NV stock a smart retirement pick2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
QIAGEN reports supervisory board member’s restricted stock unit vesting and share settlement - TipRanks
Agilent, Danaher could be potential buyers of Qiagenanalyst - MSN
Fundamentals Check: Does Qiagen NV align with a passive investing strategy2026 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push - AD HOC NEWS
Qiagen (NYSE:QGEN) Hits New 12-Month LowShould You Sell? - MarketBeat
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results - BioSpace
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
Qiagen N : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F) - marketscreener.com
Qiagen N.V. stock gains spotlight with new QuantiFERON-TB data amid genomics challenges - AD HOC NEWS
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention - BioSpace
Qiagen N.V. stock faces headwinds from genomics slowdown amid new TB test data - AD HOC NEWS
Deutsche Bank downgrades Qiagen NV (QGEN) - MSN
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
QGEN: New Data Highlights Efficacy of QuantiFERON-TB Gold Plus T - GuruFocus
Qiagen announces newly published data supporting efficacy of QuantiFERON - TipRanks
Qiagen’s TB And GI Testing Moves Draw Investor Valuation Interest - Sahm
Qiagen N.V. Stock (ISIN: NL0012169213) Faces Headwinds Amid Genomics Slowdown and Strategic Shifts - AD HOC NEWS
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays - MSN
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Moors & Cabot Inc. Acquires 154,851 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. Stock (ISIN: NL0012169213) Drops 16.85% in March Amid Diagnostics Sector Headwinds - AD HOC NEWS
BlackRock Reports 10.6% Capital and 11.8% Voting Stake in Qiagen - The Globe and Mail
Qiagen N.V. Stock (ISIN: NL0012169213) Faces Pressure Amid Life Sciences Slowdown - AD HOC NEWS
Wellington Management Group LLP Lowers Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. $QGEN Position Raised by Perbak Capital Partners LLP - MarketBeat
Dnca Finance Acquires 39,063 Shares of Qiagen N.V. $QGEN - MarketBeat
Deutsche Bank upgrades Qiagen NV (QGEN) - MSN
Qiagen (NYSE:QGEN) Stock Rating Upgraded by Deutsche Bank Aktiengesellschaft - MarketBeat
Today's Analyst Upgrade: Deutsche Bank Recommends Buy for QGEN | - GuruFocus
Deutsche Bank Upgrades Qiagen NV(QGEN.US) to Buy Rating - 富途牛牛
Korea Investment CORP Sells 93,167 Shares of Qiagen N.V. $QGEN - MarketBeat
Deutsche Bank upgrades Qiagen stock rating to buy on valuation By Investing.com - Investing.com India
Deutsche Bank upgrades Qiagen stock rating to buy on valuation - Investing.com
QIAGEN NV : Upgraded to Buy by Deutsche Bank - marketscreener.com
Deutsche Bank Upgrades Qiagen NV (QGEN) to Buy - StreetInsider
Qiagen Q2 2025 Earnings Preview - MSN
Capital International Investors Boosts Holdings in Qiagen N.V. $QGEN - MarketBeat
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):